Elisa Kieback (T-knife)
Versant funds TCR therapy biotech T-knife's $78M+ Series A to boost humanized T cell mice platform
Just a day after announcing the formation of a startup in Switzerland that will develop alternative TCR cell therapies, Versant is keeping its foot on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
